Related by context. All words. (Click for frequent words.) 74 cysteamine 67 NGX# 67 cysteamine bitartrate 66 Personalized Immunotherapy 65 phase IIb clinical 65 JAK inhibitor 65 Phenoptin 65 Phase Ib study 65 Ostarine 65 Viprinex 65 octreotide implant 65 PEG SN# 64 MOZOBIL 64 GAMMAGARD 64 otelixizumab 64 PROMACTA 64 phase IIa clinical 64 Cysteamine 64 Civacir 64 DXL# 64 bardoxolone 64 Azedra 64 alvespimycin 64 Phase 1b trial 64 Fodosine 64 AZILECT R 64 GTC recombinant human 64 ruxolitinib 64 FOLOTYN ® 64 BLA submission 64 ospemifene 64 Corlux 64 tezampanel 63 pradefovir 63 bevasiranib 63 Nasulin 63 Kuvan 63 lomitapide 63 Onconase 63 torezolid phosphate 63 dirucotide 63 Phase 2a trial 63 Microplasmin 63 selective androgen receptor modulator 63 Phase IIa trial 63 CORT # 63 iSONEP 63 ATryn ® 63 Phase IIB 63 GALNS 63 Icatibant 63 eltrombopag 63 tiapamil 63 elotuzumab 63 OHR/AVR# 63 TOCOSOL Paclitaxel 63 atacicept 63 faropenem 63 incyclinide 63 PEG PAL 63 Androxal TM 63 sapacitabine 63 EVIZON 63 LEP ETU 63 alvimopan 63 Omigard 63 Urocidin 63 Desmoteplase 63 AzaSite Plus 63 valopicitabine 63 INCB# [001] 63 HGS# 63 teduglutide 63 CoFactor 63 phase IIb 62 liposomal formulation 62 CCX# 62 R#/MEM # 62 oral ridaforolimus 62 confirmatory Phase III 62 custirsen 62 SNT MC# 62 Surfaxin LS 62 Firazyr 62 Aurexis 62 PREOS R 62 Q#IR 62 Allovectin 7 R 62 Phase 2b study 62 Solazed 62 rNAPc2 62 SinuNase 62 PXD# 62 cannabinor 62 oral prodrug 62 EFAPROXYN 62 Phase Ib clinical 62 ALN TTR# 62 Tezampanel 62 eniluracil 62 TG# [003] 62 vidofludimus 62 EndoTAG TM -1 62 Archexin 62 ATL# [001] 62 TYZEKA 62 Cleviprex TM clevidipine 62 Phase 2a clinical trials 62 CA4P 62 RSD# oral 62 rHuPH# 62 mipomersen 62 unoprostone isopropyl 62 PREOS 62 Nuvion 62 methylnaltrexone 62 registrational 62 Virulizin R 62 Locteron 62 ProSavin 62 ASONEP 62 trastuzumab DM1 62 Octreotide 62 HuMax CD4 62 Bicifadine 62 Sym# 62 safinamide 62 DAVANAT R 62 Cellegesic 62 nonclinical studies 62 Amigal 62 OvaRex R 61 R#/MEM 61 Phase 2b trial 61 ITAX 61 bicifadine 61 AeroLEF TM 61 INCB# [002] 61 OXi# 61 Factor VIIa 61 Stedivaze 61 ONTAK 61 dexpramipexole 61 LibiGel ® 61 Elagolix 61 INT# [002] 61 ARIKACE ™ 61 ATryn R 61 Pimavanserin 61 Phase IIIb clinical 61 Zybrestat 61 ocular formulation 61 Phase III Clinical Trial 61 ularitide 61 Zerenex 61 Phase #b/#a trial 61 TKM ApoB 61 Novolimus 61 PLK1 SNALP 61 Phase IIa trials 61 Phase IIb trials 61 AERx iDMS 61 oral formulation 61 XmAb# 61 MAA submission 61 Phase IIb clinical trials 61 registrational trial 61 ponatinib 61 DPX Survivac 61 Capesaris 61 CORLUX 61 Biologics License Application 61 drug ISA# 61 tafamidis 61 Ketotransdel 61 nephropathic cystinosis 61 OvaRex ® MAb 61 brivaracetam 61 Entereg R 61 Phase Ib 61 urocortin 2 61 Phase IIb clinical 61 peginesatide 61 oral taxane 61 Ocrelizumab 61 BLA filing 61 ELADUR 61 Chrysalin 61 TRO# 61 Chemophase 61 Zenvia ™ 61 TELINTRA 61 Phase #b/#a 61 vilazodone 61 KNS # 61 Zelrix 61 squalamine 61 omacetaxine 61 Catena ® 61 Phase Ib clinical trials 61 forodesine 61 Relivar 61 optimal dosing regimens 61 ALN PCS 61 aldehyde dehydrogenase ALDH2 deficiency 61 Acapodene 61 CD# CEA 61 IL# PE#QQR 61 Pivotal Phase 61 UPLYSO 61 HCV protease inhibitor 61 Neurodex 61 Bezielle 61 cangrelor 61 INTERCEPT platelets 61 TRANSDUR Sufentanil 61 fenretinide 61 pertuzumab 60 Phase III clinical 60 investigational therapies 60 phase IIb trial 60 prGCD 60 Alvesco R 60 CINTREDEKIN BESUDOTOX 60 subcutaneous formulation 60 MAXY G# 60 Anavex #-# 60 PDE4 inhibitor 60 liprotamase 60 NEBIDO 60 proprietary transdermal patch 60 Leukine 60 zileuton 60 SILENOR TM 60 Technosphere Insulin 60 Phase IIb 60 JAK1 60 vernakalant oral 60 Probuphine 60 ORENCIA R 60 phase IIa 60 IND submission 60 NPSP# 60 MAGE A3 ASCI 60 EVIZON TM 60 MEK inhibitor 60 volociximab 60 Asentar 60 ZEGERID Capsules 60 SILENOR 60 Phase 2b clinical 60 FavId 60 HGS ETR1 60 Panzem R 60 LE SN# 60 OncoVEX 60 pomalidomide 60 BioVant 60 CR# vcMMAE 60 MoxDuo IR 60 CEQ# 60 Panzem R NCD 60 MBP# [001] 60 MEK inhibitors 60 Amrubicin 60 huC# DM4 60 Genasense ® oblimersen 60 obatoclax 60 GAP #B# 60 maribavir 60 nalbuphine ER 60 SinuNase TM 60 ADAGIO study 60 tanespimycin 60 TBC# 60 mertansine 60 investigational humanized monoclonal antibody 60 Prestara 60 tolevamer 60 AZILECT ® 60 CRMD# 60 SEPET TM 60 davunetide 60 tezampanel NGX# 60 JAK inhibitors 60 rFIXFc 60 Phase 2a 60 GLPG# 60 ocrelizumab 60 ELND# 60 Varespladib 60 FOLOTYN 60 Exherin TM 60 PSN# [002] 60 Phase IIa 60 NUVIGIL 60 BENLYSTA ® 60 Panzem 60 OMNARIS HFA 60 THALOMID 60 Zingo TM 60 Increlex R 60 ISIS # 60 AAG geldanamycin analog 60 Fortical R 60 ostarine 60 YONDELIS 60 tecarfarin 60 ZYBRESTAT 60 Elocalcitol 60 pralatrexate 60 lumiliximab 60 tasimelteon 60 IIa trial 60 lucinactant 60 Azacitidine 60 deforolimus 60 daclizumab 60 targeted radiotherapeutic 60 Insegia 60 rhThrombin 60 EDEMA3 trial 60 Azixa 60 reslizumab 60 cancer immunotherapies 60 omega interferon 60 Orazol 60 AVE# 60 Octreolin 60 Annamycin 59 Alfimeprase 59 Safinamide 59 preclinically 59 TLK# 59 vivo validation 59 TH# [003] 59 REPLAGAL 59 Hedgehog antagonist 59 interferon gamma 1b 59 generation purine nucleoside 59 OMNARIS Nasal Spray 59 oral calcitonin 59 ONCONASE 59 opioid induced bowel dysfunction 59 Fabry Disease 59 Behcet uveitis 59 octreotide acetate 59 alagebrium 59 Proquin XR 59 Symadex 59 SNALP technology 59 AMD# [003] 59 Phase 2b clinical trials 59 visilizumab 59 Dacogen injection 59 humanized anti 59 zileuton CR 59 Cethrin 59 Targretin capsules 59 Loramyc R 59 teriflunomide 59 eprotirome 59 sitaxsentan 59 Xanafide 59 Rebif ® 59 crofelemer 59 Altastaph 59 Granulocyte Colony Stimulating Factor 59 HuMax EGFr 59 RSD# iv 59 amrubicin 59 QNEXA 59 budesonide foam 59 Besivance 59 GLP toxicology studies 59 T Pred 59 RhuDex ® 59 Soliris eculizumab 59 Degarelix 59 Evoltra ® 59 thymalfasin 59 veltuzumab 59 Shigamabs ® 59 RECOTHROM R 59 Diabetic Macular Edema 59 acetonide FA 59 pegloticase 59 Azedra TM 59 rindopepimut 59 axitinib 59 Raptiva ® 59 Fibrin Pad 59 C1 INH 59 Mipomersen 59 Proxinium TM 59 EOquin TM 59 RAPTIVA R 59 virus HCV protease inhibitor 59 Dasatinib 59 MYDICAR 59 tivozanib 59 ozarelix 59 HuLuc# 59 Squalamine 59 CIMZIA TM 59 Unit Dose Budesonide 59 CTAP# Capsules 59 PRX # 59 Trizytek 59 HCD# [002] 59 GSK# [002] 59 cMET 59 Marqibo 59 #D#C# 59 Iluvien ® 59 successfully commercialize Iluvien 59 Urokinase 59 PhosLo 59 Tracleer R 59 IAP inhibitor 59 Phase IIa clinical 59 TACI Ig 59 Lixivaptan 59 SinuNase ™ 59 Spiegelmer ® 59 RIGScan CR 59 blood clot dissolver 59 Phase 1a clinical 59 ganetespib 59 Exelixis compounds 59 MONOVISC 59 phase IIb study 59 Prodarsan ® 59 metaglidasen 59 Intermezzo R 59 voclosporin 59 Ventavis 59 Tamibarotene 59 Traficet EN 59 herpetic keratitis 59 pharmacokinetic PK study 59 Serdaxin 59 Cetrorelix 59 BrachySil TM 59 ENMD # 59 Cinryze ™ 59 phase Ib 59 IV APAP 59 Veronate 59 Initiate Clinical Trial 59 confirmatory clinical 59 budiodarone 59 Phase 2b Clinical Trial 59 Locteron ® 59 HuMax CD# 59 PrevOnco 59 PRECISE trial 59 celgosivir 59 AEG# 59 Lisofylline LSF 59 SonoLysis 59 TOLAMBA 59 NEUMUNE 59 danoprevir 59 PHX# 59 PRT# 59 panitumumab 59 USL# 59 ataluren 59 Revimmune 59 HQK 59 Cintredekin Besudotox 59 efficacy tolerability 59 Fx #A 59 naronapride 59 RG# [001] 59 lixivaptan 59 Cloretazine 59 orally administered inhibitor 59 oral gallium 59 PEGPH# 59 PSMA ADC 59 dextromethorphan quinidine 59 midstage trials 59 StaphVAX 59 Viramidine 59 silodosin 59 Interferon alpha 59 velaglucerase alfa 59 omecamtiv mecarbil 59 tranilast 59 ALN TTR 59 multicenter Phase II 59 favorable pharmacokinetic profile 59 PDE# inhibitors 59 Myocet 59 Santhera 59 Rasagiline 59 Phase IIIb 58 Pennsaid R 58 rhC1INH 58 RSD# 58 Memryte 58 tramiprosate 58 Allovectin 7 58 Pivotal Phase III 58 oxypurinol 58 Trofex 58 investigational antiplatelet agent 58 HepeX B 58 darapladib 58 TRANSDUR Bupivacaine 58 ALTU 58 MAP# 58 NV1FGF 58 trial evaluating PRX# 58 ALN VSP 58 Vilazodone 58 belinostat 58 molecular imaging radiopharmaceutical 58 cintredekin besudotox 58 Hematide ™ 58 Frova ® 58 glucokinase activator 58 Febuxostat 58 Plicera 58 PRTX 58 initiate Phase 1b 58 PS# [001] 58 Onco TCS 58 eszopiclone 58 RNAi therapeutic targeting PCSK9 58 AzaSite Xtra 58 IMA# 58 synthetic retinoid 58 JAK2 inhibitor 58 MYDICAR ® 58 induced macular edema 58 HCV protease inhibitors 58 Bioral 58 Syntonix 58 picoplatin 58 THR beta agonist 58 PrevOnco ™ 58 RGB # 58 Phase III trials 58 Study GL# 58 Alzhemed TM 58 baminercept 58 ulimorelin 58 Xcytrin R 58 Ophena TM 58 candidate epratuzumab 58 Plenaxis TM 58 histone deacetylase HDAC inhibitor 58 Clolar ® 58 vemurafenib 58 Iloperidone 58 plasma kallikrein inhibitor 58 ganaxolone 58 Neuradiab 58 Somatuline Autogel 58 orBec 58 Aerosurf 58 Topical Interferon Alpha 2b 58 placebo controlled clinical 58 ZADAXIN ® 58 randomized controlled Phase 58 IMiDs 58 Restanza 58 Virulizin ® 58 Increlex ® 58 Phase 2a clinical 58 Cotara 58 HoFH 58 trastuzumab DM1 T DM1 58 RAPAFLO 58 Rescula 58 L BLP# 58 PEG Interferon lambda 58 elacytarabine 58 refractory gout 58 Sanctura XR 58 CD# antibody [001] 58 interferon beta 1b 58 IRX 2 58 Phase #/#a 58 RELISTOR ® 58 CYT# 58 Neulasta ® 58 DPP4 inhibitor 58 FROVA 58 Cobalamin 58 MAXY alpha 58 Pafuramidine 58 BRAF inhibitor 58 CD# monoclonal antibody 58 Dextofisopam 58 ANAVEX #-# [003] 58 palonosetron 58 MyVax R 58 systemically administered 58 Ramoplanin 58 receptor tyrosine kinase inhibitor 58 sodium thiosulfate STS 58 Captisol enabled 58 Acetavance 58 preclinical efficacy 58 Lux Biosciences 58 Bronchitol 58 investigational pan BCR 58 FACTIVE R gemifloxacin 58 randomized Phase 2b 58 intranasal formulation 58 SUPPRELIN R LA 58 clinical pharmacology studies 58 Bendavia 58 sargramostim 58 ONCONASE R 58 humanized antibodies 58 Specifid 58 subcutaneously administered 58 Phase III Clinical Trials 58 nitazoxanide 58 oral bioavailability 58 ALVESCO HFA 58 Loramyc 58 MGCD# [001] 58 Dynepo 58 Exelbine 58 GED aPC 58 histamine dihydrochloride 58 oral cladribine 58 CRLX# 58 Urocidin TM 58 novel VDA molecule 58 Onalta 58 Targretin 58 alfimeprase 58 Phenserine 58 CIP TRAMADOL ER 58 maximally tolerated dose 58 Puricase 58 rALLy trial 58 Anthim 58 PD LID 58 Tarvacin TM 58 telomerase therapeutic 58 adipiplon 58 Ophthotech 58 ABILIFY ® 58 immunomodulatory therapy 58 Somatuline R Autogel R 58 ACAPODENE 58 highly selective adenosine 58 Reolysin 58 Aviptadil 58 Nexavar sorafenib 58 fosbretabulin 58 Omacetaxine 58 XL# XL# 58 compound INCB# 58 TELCYTA 58 Hectorol R 58 Tasimelteon 58 PLX cells 58 EGS# 58 Zavesca r 58 PF # [002] 58 AQ4N 58 IPLEX 58 ZYFLO CR 58 pivotal Phase III 58 fostamatinib 58 Rhucin 58 davunetide intranasal AL 58 Retisert 58 velafermin belinostat 58 P#X# antagonist 58 oral methylnaltrexone 58 ibudilast 58 Aclidinium 58 CRD5 58 Amplimexon 58 NVA# 58 Synavive 58 IAP inhibitors 58 Protexia R 58 Shigamabs R 58 riociguat 58 prostone 58 beta 1a 58 betrixaban 58 hypoxia activated prodrug 58 Biologics License Application BLA 58 dextofisopam 58 Cethromycin 58 initiate Phase 2b 58 vascular disrupting agents 58 Nanobody ® 58 intravitreal injection 58 acyclovir Lauriad R 58 Bioral Amphotericin B 58 eculizumab 58 Phase #b/#a clinical 58 investigational drug 58 Randomized Phase 58 SYCREST 58 rThrombin 58 SARMs 58 BAY #-# 58 ReN# 58 Ceflatonin 58 Gattex 58 BNC# 58 Saforis 58 microplasmin 58 LHRH antagonist 58 MDV# 58 CDP# 58 GFT# 58 Voraxaze 58 Anturol TM 58 solanezumab 58 Itopride 58 QRxPharma 58 Neo Kidney Augment 58 DEB# 58 albinterferon alfa 2b 58 Vandetanib 58 omacetaxine mepesuccinate 58 pharmacokinetic studies 58 rBChE 58 APF# 58 Pirfenidone 58 pharmacokinetic PK 58 aclidinium bromide 58 Neo Urinary Conduit 58 ILUVIEN ® 57 JOULFERON 57 clinical trials 57 RDEA# 57 entinostat 57 Viprinex TM 57 Aeroquin 57 dyskinesia PD LID 57 rxRNA 57 tubulin inhibitor 57 investigational monoclonal antibody 57 Preos 57 Menerba 57 Indaflex TM 57 Resten NG 57 HEPLISAV 57 dose cohort 57 injectable formulation 57 GLP toxicology 57 Nanobody R 57 anidulafungin 57 Phase III Pivotal 57 Fibrillex TM 57 AMD# [002] 57 therapeutic monoclonal antibody 57 RNAi therapeutic targeting 57 vorinostat 57 NeuroSTAT ® 57 Prostate AdenoCarcinoma Treatment 57 bazedoxifene 57 ancrod 57 JP-#/fipamezole 57 Riquent 57 Meets Primary Endpoint 57 Exherin 57 preclinical studies 57 OMAPRO 57 angiogenesis inhibitor 57 Solulin 57 SUCCEED trial 57 GRNVAC1 57 talactoferrin 57 HuMax TAC 57 ZOLINZA 57 Ventavis ® 57 calcitonin 57 vosaroxin 57 Triolex 57 catheter occlusion 57 Numax 57 NOX E# 57 Thiarabine 57 thrombolytic agent 57 EGRIFTA TM 57 LymphoStat B belimumab 57 Aegera 57 Tesetaxel 57 Poly ICR 57 Solasia 57 Clavis Pharma 57 CCR5 antagonist 57 Firdapse 57 Prodarsan R 57 NP2 Enkephalin 57 OLEPTRO TM 57 VEGF Trap 57 Vectibix panitumumab 57 perifosine 57 TAXUS TM 57 Soliris TM eculizumab 57 preclinical 57 Clonicel 57 luliconazole 57 HDL Selective Delipidation 57 bafetinib 57 oral FTY# 57 RECOTHROM ® 57 Completes Patient Enrollment 57 tremelimumab 57 HGS ETR2 57 INTEGRILIN 57 Evoltra TM 57 QLT# 57 BRIM3 57 SCOLR Pharma 57 WILEX 57 bortezomib Velcade 57 Dapagliflozin 57 Sulonex TM 57 XP# XP# 57 LAF# 57 Targeted Chemotherapy 57 Zenvia Phase III 57 Entereg TM 57 Orphan Drug designation 57 Abiraterone acetate 57 Ophena 57 TREANDA 57 MAXY VII 57 phase 2a 57 indibulin 57 lorvotuzumab mertansine 57 injectable formulations 57 Filgrastim 57 Duromist ™ 57 LEVADEX TM 57 Urocortin 2 57 MyVax 57 DCCR 57 exon skipping 57 Zalbin 57 ADVEXIN clinical 57 BCX# 57 ProLindac 57 Luveniq 57 ESBA# 57 CINQUIL 57 ELACYT 57 rilonacept 57 Phase IIa clinical trials 57 lintuzumab 57 Lupuzor 57 Dalbavancin 57 Tekturna Rasilez 57 2 methoxyestradiol 57 Kamada AAT 57 Solazed TM 57 MEK inhibitor RDEA# 57 Dupuytren Contracture 57 selective GR 57 corticosteroid dexamethasone 57 tesmilifene 57 Silodosin 57 Glufosfamide 57 ApoB SNALP 57 milatuzumab 57 non nucleoside HCV 57 Pralatrexate 57 PANVAC VF 57 aclidinium 57 Oracea TM 57 ENTEREG ® 57 TRIOLEX 57 ARIKACE 57 lesinurad 57 MACUGEN 57 CBLC# 57 ThermoDox R 57 Vascugel 57 Celator 57 Cinquil 57 Bendamustine 57 EDEMA3 57 Protexia ® 57 SCIB1 57 Aganocide 57 drug eluting coronary stent 57 VIAject R 57 Abbokinase 57 nab paclitaxel 57 Pivotal Trial 57 Phase IIb III 57 oral salmon calcitonin 57 defensin mimetic antibiotic 57 Ferumoxytol 57 Xcellerated T Cells 57 DAVANAT 57 pivotal bioequivalence 57 PEGylated 57 SUTENT ® 57 cilengitide 57 teplizumab 57 Kepivance 57 DDP# 57 Emezine 57 denufosol 57 CCR9 antagonist 57 VersaFilm 57 GGF2 57 inhaled iloprost 57 Hematide TM 57 AVN# [001] 57 MGN# 57 INS# [001] 57 PROMUS Element Stent 57 IMiD 57 exenatide LAR 57 Tanespimycin 57 ambrisentan 57 ® natalizumab 57 ENRICH trial 57 CytoFabTM 57 Stavzor 57 inhaled AAT 57 filgrastim 57 TRAIL receptor antibodies 57 ALKS 57 Phase IIb trial 57 CYCLOSET 57 Rhucin ® 57 Amphotericin B 57 topical formulations 57 novel peptides 57 amifampridine phosphate 57 lintuzumab SGN 57 r hGH 57 pharmacokinetic characteristics 57 Phase Ib II 57 Torisel 57 LEUKINE 57 pimavanserin 57 trodusquemine 57 sodium Injection 57 Keppra XR 57 MyVax ® 57 JZP 57 REOLYSIN ® 57 dosing cohort 57 Fentanyl TAIFUN R 57 ICA # 57 bifeprunox 57 Arcalyst 57 FM VP4 57 inhibitor RG# 57 sorafenib tablets 57 hGH CTP 57 Heplisav 57 Visudyne R 57 Cloretazine ® 57 Virium 57 Arikace 57 epigenetic therapies 57 midstage clinical 57 Celladon Corporation 57 Cloretazine R VNP#M 57 Loramyc ® 57 tolvaptan 57 sodium glucose cotransporter 57 non alcoholic steatohepatitis 57 faropenem medoxomil 57 Opexa 57 Denosumab 57 ONCASPAR 57 Myolimus 57 Initiates Clinical 57 Cutanea 57 Biopump 57 miconazole MBT 57 Prolacria 57 therapeutic monoclonal antibodies 57 blinatumomab 57 NDA submission 57 regorafenib 57 6R BH4 57 samalizumab 57 isavuconazole 57 Phase III randomized controlled 57 abiraterone acetate 56 CYT# potent vascular disrupting 56 Renvela 56 Gabapentin GR